相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A US Food and Drug Administration Systematic Analysis
Kelly J. Norsworthy et al.
CLINICAL CANCER RESEARCH (2020)
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
Theodore C. Tarver et al.
BLOOD ADVANCES (2020)
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation
Kelly J. Norsworthy et al.
CLINICAL CANCER RESEARCH (2019)
The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis
Panagiotis Tsapogas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
FLT3 Inhibitor-Associated Neutrophilic Dermatoses
Nisha Varadarajan et al.
JAMA DERMATOLOGY (2016)
Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITDAML
Amy Sexauer et al.
BLOOD (2012)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study
P. Chevallier et al.
LEUKEMIA (2011)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Mutant FLT3:: A direct target of sorafenib in acute myelogenous leukemia
Weiguo Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia
Adam J. Mead et al.
BLOOD (2007)
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
Daniel J. DeAngelo et al.
BLOOD (2006)
Prognostic index for adult patients with acute myeloid leukemia in first relapse
DA Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
W Fiedler et al.
BLOOD (2005)
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
BD Smith et al.
BLOOD (2004)
The role of FLT3 in haematopoietic malignancies
DL Stirewalt et al.
NATURE REVIEWS CANCER (2003)
分享论文
